Popular terms

Factor Viii topics
Factor Viii
Nucleotide
Antibodies
Polynucleotide
Polypeptide
Sialic Acid
Circulatory
Recombinant
Ethylene Glycol
Coagulation
Hemophilia
Physiologic
Endogenous
Prophylaxis
Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor Viii patents



      

This page is updated frequently with new Factor Viii-related patent applications.




Date/App# patent app List of recent Factor Viii-related patents
02/04/16
20160031968 
 Variant factor viii polypeptides and methods of their production and use patent thumbnailnew patent Variant factor viii polypeptides and methods of their production and use
This disclosure relates to variant factor viii polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant factor viii polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop.
Bayer Healthcare Llc


02/04/16
20160030529 
 Targeted elimination of factor viii immune cells patent thumbnailnew patent Targeted elimination of factor viii immune cells
This disclosure relates to composition and methods for improving blood clotting in a subject that developed anti-factor viii antibodies. In certain embodiments, this disclosure contemplates a conjugate comprising a toxin, e.g., ricin, abrin, saporin, coupled to factor viii or functional variant thereof either through a linking group or as a fusion protein..
Emory University


02/04/16
20160030524 
 Recombinant factor viii formulations patent thumbnailnew patent Recombinant factor viii formulations
Provided are liquid and lyophilized recombinant factor viii formulations, including formulations for polymer-conjugated fviii such as pegylated factor viii.. .
Bayer Healthcare Llc


01/07/16
20160003850 
 Methods and compositions for diagnosis and prognosis of renal injury and renal failure patent thumbnailMethods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of coagulation factor x, coagulation factor v, soluble receptor tyrosine-protein kinase erbb-2, interferon beta, c-type lectin domain family 11 member a, glyceraldehyde-3-phosphate dehydrogenase, interferon omega-1, coagulation factor viii, thrombin-antithrombin-iii complex, and soluble tumor necrosis factor ligand superfamily member 13b as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.


01/07/16
20160002314 
 Factor viii variants having a decreased cellular uptake patent thumbnailFactor viii variants having a decreased cellular uptake
The present invention relates to modified coagulation factors. In particular, the present invention relates to modied factor viii molecules having decreased cellular uptake..
Sanquin Blood Supply Foundation


01/07/16
20160000884 
 Liquid factor viii formulations patent thumbnailLiquid factor viii formulations
The invention is directed to a liquid, aqueous formulation of coagulation factor viii, comprising a factor viii molecule, a calcium salt in a concentration of more than 10 mm, and a saccharide and/or polyol in a concentration of at least 100 mm, wherein the formulation has a ph from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation factor viii, the method comprising the steps of: (i) providing one or more liquid formulations comprising factor viii to be tested; (ii) adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) analysing the incubated solutions of (ii) for the presence of dissociated factor viii; and (iv) selecting one or more formulation(s) having a desired low level of dissociated factor viii..
Novo Nordisk A/s


12/31/15
20150376612 
 Ccctc-binding factor (ctcf) rna interactome patent thumbnailCcctc-binding factor (ctcf) rna interactome
This invention relates to methods and compositions for selectively reactivating or downregulating certain genes, e.g., genes regulated by zinc-finger protein ccctc-binding factor (ctcf) on autosomes (e.g., imprinted genes, tumor suppressors, cancer) and the inactive x chromosome (xi), e.g., genes associated with x-linked diseases, e.g., rett syndrome, factor viii or ix deficiency, fragile x syndrome, duchenne muscular dystrophy, and pnh, in heterozygous females carrying a mutated allele, in addition to a functional wildtype or hypomorphic allele.. .
The General Hospital Corporation


12/31/15
20150376262 
 Factor viii molecules with reduced vwf binding patent thumbnailFactor viii molecules with reduced vwf binding
The present invention relates to a recombinant factor viii molecule, wherein said molecule has reduced vwf binding capacity, and wherein said molecule is covalently conjugated with at least one side group.. .
Novo Nordisk A/s


12/24/15
20150366947 
 A  purifying therapeutic proteins patent thumbnailA purifying therapeutic proteins
The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, factor viii and von willebrand factor (vwf), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, factor viii and vwf through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, factor viii and vwf which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in the solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or factor viii and/or vwf recovered by such methods, and uses thereof..
Csl Behring Gmbh


12/17/15
20150361158 
 Optimized factor viii gene patent thumbnailOptimized factor viii gene
The present invention provides codon optimized factor viii sequences, vectors and host cells comprising codon optimized factor viii sequences, polypeptides encoded by codon optimized factor viii sequences, and methods of producing such polypeptides.. .
Biogen Ma Inc.


12/10/15
20150353625 

Variant of antihemophilic factor viii having increased specific activity


The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor viii having increased specific activity in comparison to known factor viii products..
Baxalta Gmbh


12/10/15
20150352190 

Modified factor viii


Methods of treating patients with factor viii deficiency by administration of modified porcine factor viii are disclosed. The particular modified porcine factor viii is one in which most of the b domain has been removed through genetic engineering.
Emory University


11/26/15
20150337028 

Double mutant coagulation factor viii and methods thereof


A double mutant b-domain deleted factor viii gene having mutations at phe309ser and asp519val, respectively, is disclosed for use in the field of haemophilia therapeutics. The disclosure a double mutant b-domain deleted factor viii protein having mutations at phe309ser and asp519val respectively, is also disclosed, as well as methods of producing the same.
Christian Medical College


11/05/15
20150315263 

Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof


The present disclosure relates to purification of factor viii protein and/or its fragments from various sources by employing monolith based pseudobioaffinity purification methods. In particular, l-histidine over cim monolith [histidine ligand affinity chromatography (hlac)] is used for the purification of wild-type factor viii from plasma cryoprecipitate, recombinant b-domain deleted factor viii (rbdd-fviii) expressed in various host systems and recombinant factor viii light chain expressed in pichia pastoris.
Centre For Bioseparation Technology - Vit


10/29/15
20150306250 

Factor viii mutation repair and tolerance induction


Methods of treating hemophilia a in a subject with an f8 gene mutation, wherein the f8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded fviii protein of the subject compared to the non-repaired f8 gene. The invention also includes methods of inducing immune tolerance to a fviii replacement product ((r)fviii) in a subject having a fviii deficiency, wherein the f8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement fviii protein product.
The United States Government As Represented By The Deparment Of Veterans Affairs


10/29/15
20150306192 

Modified fviii apitope peptides


The present invention provides peptides partly derivable from fviii which are capable of binding to an mhc class ii molecule without further antigen processing and being recognised by a factor viii specific t cell. In particular, the present invention provides peptides comprising the sequence dnimvtfrnqasrpy or prcltryyssfvnme with modifications at the n- and c-termini.
Apitope International Nv


10/08/15
20150283267 

Vectors for liver-directed gene therapy of hemophilia and methods and use thereof


The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor ix or factor viii genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor ix or factor viii genes are also disclosed.

10/01/15
20150273082 

Optimised coding sequence and promoter


An optimized coding sequence of human blood clotting factor eight (viii) and a promoter may be used in vectors, such as raav, for introduction of factor viii, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases.
St. Jude Children's Research Hospital


09/24/15
20150266944 

Methods of using fviii polypeptide


The present invention provides methods of reducing or decreasing the annualized bleeding rate of a human subject having hemophilia by administering a long acting factor viii polypeptide. The long-acting fviii polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.
Biogen Idec Ma Inc.


09/24/15
20150266943 

Factor viii complex with xten and von willebrand factor protein, and uses thereof


The present invention includes a chimeric protein comprising a vwf protein with d′ domain and d3 domain of vwf, one or more xten sequence, and a fviii protein, wherein the vwf fragment, the xten sequence, or the fviii protein are linked to or associated with each other. The chimeric protein can further comprise one or more ig constant region or a portion thereof (e.g., an fc region).
Biogen Ma Inc.


08/27/15
20150240287 

Method for evaluating blood coagulation reaction


Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor viii (fviii). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor xi (fxia) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor viii (fviii) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator..
Public University Corporation Nara Medical University


08/27/15
20150239984 

Therapeutic factor viii antibodies


The present invention relates to therapeutic fviii antibodies. In particular, the present invention relates to fviii antibodies having the ability to prolong the circulatory half life of fviii.
Novo Nordisk A/s


08/13/15
20150225717 

Selective reactivation of genes on the inactive x chromosome


Methods and compositions for selectively reactivating genes on the inactive x chromosome (xi) in a locus-specific manner, e.g., genes associated with x-linked diseases, e.g., rett syndrome, factor viii or ix deficiency, fragile x syndrome, duchenne muscular dystrophy, and pnh, in heterozygous females.. .
The General Hospital Corporation


08/13/15
20150225472 

Methods for producing recombinant factor viii chains from non-filamentous fungi, their functional reconstitution and applications thereof


A process of producing heavy chain peptide and/or light chain peptide of recombinant factor viii protein includes using the pichia pastoris expression system. A process of producing a functional recombinant factor viii protein by reconstituting the heavy chain and light chain produced using said pichia pastoris expression system.
Christian Medical College


08/13/15
20150224203 

Factor viii conjugates


The present invention relates to fviii conjugated to heparosan (hep) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia..
Novo Nordisk A/s


08/06/15
20150216944 

Allelic variants of human factor viii


Disclosed are compositions and methods related to factor viii.. .
Haplomics, Inc


07/30/15
20150210737 

Integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma


The purification carried out by an all-chromatography scheme, avoids the use of ethanol precipitation in the entire manufacturing process of the said four plasma products. The invention describes an integrated process for purifying four different proteins from human plasma to high therapeutic grade purity levels, with a potential to purify more therapeutic proteins from a given plasma sample by incorporating additional chromatography steps in the sequence..

07/16/15
20150197552 

Compositions and methods of treatment of black hemophiliac patients


It has been determined that most mutations in factor viii occur in multiple haplotypes, not primarily in one haplotype. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplotype.
Haplomics, Inc.


07/16/15
20150196017 

Compositions and methods of treatment of black hemophiliac patients


It has been determined that most mutations in factor viii occur in multiple haplotypes, not primarily in one haplotype. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplotype.
Haplomics, Inc.


07/09/15
20150191526 

Cell line expressing single chain factor viii polypeptides and uses thereof


The present invention provides cell lines for producing single chain fviii polypeptides, e.g., chimeric single chain fviii polypeptides, methods of producing single chain fviii polypeptides, single chain fviii polypeptides, and methods of treating hemophilia a with a single chain factor viii polypeptide.. .
Biogen Idec Ma Inc.


07/09/15
20150190478 

New protecting compositions for recombinantly produced factor vii


A histidine-free composition comprising: a high purity factor viii (r-factor viii); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor viii; an amount of calcium chloride for specific stabilization of factor viii.. .
Octapharma Ag


06/11/15
20150158930 

Factor viii sequences


There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor viii protein, wherein the portion of the nucleotide sequence encoding for the b domain of the factor viii protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to seq id no: 4 and which comprises six asparagine residues. Also provided is a functional factor viii protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g.
St. Jude Children's Research Hospital


06/11/15
20150158929 

Factor viii compositions and methods of making and using same


The present invention relates to compositions comprising factor viii coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor viii-related diseases, disorders, and conditions.. .
Biogen Idec Ma Inc.


06/11/15
20150158906 

Method of purifying therapeutic proteins


Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or factor viii and/or vwf recovered by such methods, and uses thereof.. .

03/26/15
20150087593 

Coagulation factor viii with reduced immunogenicity


B. Modification of said epitope(s) by eliminating at least one hydrophobic aminoacid residues in position p1 and/or p7, substituting at least one hydrophobic aminoacid residue in position p1 and/or p7 with a non-hydrophobic residue, or adding a non-hydrophobic residue in position p1 and/or p7..

03/19/15
20150080304 

Treatment and prevention of radiation injury using mfg-e8


Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor viii (mfg-e8).. .
The Feinstein Institute For Medical Research


03/19/15
20150079072 

Assays to monitor bleeding disorders


The present invention provides methods of dosing factor viii or factor ix chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated fix protein in a test sample.
Biogen Idec Hemophilia Inc.


03/12/15
20150071883 

Adeno-associated virus factor viii vectors


The invention provides improved adeno-associated virus (aav) factor viii (fviii) vectors, including aav fviii vectors that produce a functional factor viii polypeptide and aav fviii vectors with high expression activity.. .
Biomarin Pharmaceutical Inc.


02/26/15
20150056271 

Compositions and methods for enhancing coagulation factor viii function


factor viii variants and methods of use thereof are disclosed.. .
The Children's Hospital Of Philadelphia


02/05/15
20150038422 

Unit dosage forms of pharmaceutical compositions comprising a polymer-factor viii polypeptide conjugate


Conjugates of a factor viii moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof.
Nektar Therapeutics


02/05/15
20150038421 

Factor viii compositions and methods of making and using same


The present invention relates to compositions comprising factor viii coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor viii-related diseases, disorders, and conditions.. .
Amunix Operating Inc.


02/05/15
20150037301 

Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface


The invention relates to a recombinant factor viii that includes one or more mutations at an interface of a1 and c2 domains of recombinant factor viii. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity.
University Of Rochester


01/22/15
20150025010 

Novel albumin-free factor viii formulations


A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8.
University Of Connecticut


01/22/15
20150023959 

Chimeric factor viii polypeptides and uses thereof


The present invention provides a vwf fragment comprising the d′ domain and d3 domain of vwf, a chimeric protein comprising the vwf fragment and a heterologous moiety, or a chimeric protein comprising the vwf fragment and a fviii protein and methods of using the same. A polypeptide chain comprising a vwf fragment of the invention binds to or is associated with a polypeptide chain comprising a fviii protein and the polypeptide chain comprising the vwf fragment can prevent or inhibit binding of endogenous vwf to the fviii protein.
Biogen Idec Ma Inc.


01/22/15
20150023946 

Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii


The present invention relates to pharmaceutical preparations comprising factor viii, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a factor viii, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of factor viii by co-adminstration of a sulfated glycosaminoglycan and a hyaluronidase..
Csl Behring Gmbh


01/01/15
20150005473 

Recombinant expression vector system for variants of coagulation factor viii and von willebrand factor


Disclosed is an expression vector system for variants of coagulation factor viii (fviii) and von willebrand factor (vwf). In detail, mutant vwf the size of which is significantly reduced by deleting exons but which has remarkably increased fviii stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with fviii are disclosed.
Korea University Industrial & Academic Collaborative Foundation


01/01/15
20150004218 

Compositions and methods for immune tolerance induction


Methods and compositions to reduce immunogenicity of proteins are disclosed. Compositions comprising therapeutic proteins (such as factor viii or any other protein or peptide) complexed with liposomes comprising ps and pc (ps liposomes), or comprising ps, pi and pc and, optionally, cholesterol (ps/pi liposomes) may be used..
The Research Foundation For The State University Of New York




Factor Viii topics: Factor Viii, Nucleotide, Antibodies, Polynucleotide, Polypeptide, Sialic Acid, Circulatory, Recombinant, Ethylene Glycol, Coagulation, Hemophilia, Physiologic, Endogenous, Prophylaxis, Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor Viii for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor Viii with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.697

4794

2 - 1 - 102